SCHEMBL7222803

SCHEMBL7222803

CCOCCOc1ccc(COc2ccc3c(c2)C=C(C(=O)OC)CCS3(=O)=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.38
RAB9A P51151 5/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
FFAR1 O14842 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PPARG P37231 2/20 0.35
PPARD Q03181 2/20 0.35
PPARA Q07869 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
ACACB O00763 1/20 0.35
APP P05067 3/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
HSP90AA1 P07900 1/20 0.34
MRGPRX4 Q96LA9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7215817 0.94 NPC1 (0.38) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL7218066 0.91 NPC1 (0.41) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL7221445 0.91 FFAR1 (0.39) NPC1RAB9ASMN1; SMN2FFAR1RXRA
SCHEMBL7218242 0.89 NPC1 (0.37) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL7968606 0.88 MAPT (0.36) NPC1RAB9AMAPTKDM4EALDH1A1
SCHEMBL7222605 0.86 MAOB (0.44) FFAR1PPARDMRGPRX4
SCHEMBL7218226 0.86 PARP14 (0.34) MAPTMEN1KMT2ASMN1; SMN2L3MBTL1
SCHEMBL7216505 0.85 NPC1 (0.46) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL7218076 0.85 S1PR1 (0.36) MAPTMEN1KMT2ASMN1; SMN2FFAR1
SCHEMBL7215961 0.84 HRH3 (0.39) NPC1RAB9AKMT2ASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed